uently Asked Questions about IGF-1 DES(1-3)

sked Questions about IGF-1 DES(1-3)

What is the main difference between IGF-1 DES(1-3) and natural IGF-1?**

t is the main difference between IGF-1 DES(1-3) and natural IGF-1?** A: The primary difference is structural: IGF-1 DES(1-3) is a modified version of IGF-1 where the first three N-terminal amino acids are removed. This alteration leads to IGF-1 DES(1-3) having a higher binding affinity for the IGF-1 receptor and a reduced binding to IGF-binding proteins (IGFBPs), theoretically allowing for more localized and immediate activity at target tissues compared to native IGF-1. (Source: PubChem)

How is IGF-1 DES(1-3) typically administered?**

lly administered?** A: IGF-1 DES(1-3) is an injectable peptide. Its typical administration route involves subcutaneous or intramuscular injection, often localized to the tissue or muscle group of interest to maximize its local effects. (Source: general knowledge of peptide administration).

Is IGF-1 DES(1-3) approved for any medical uses?**

pproved for any medical uses?** A: No, IGF-1 DES(1-3) is not approved by regulatory bodies like the FDA for human therapeutic use. It is considered an investigational research chemical, and its use in humans is outside of established medical guidelines. (Source: FDA Unapproved Drugs Database, DrugBank).

Can IGF-1 DES(1-3) lead to hypoglycemia?**

n IGF-1 DES(1-3) lead to hypoglycemia?** A: Yes, like native IGF-1, IGF-1 DES(1-3) can have insulin-mimetic effects, which means it has the potential to lower blood glucose levels. Individuals using this compound should be mindful of the signs of hypoglycemia, such as sweating or dizziness. (Source: theoretical extrapolation from IGF-1 effects).

What are the main concerns regarding the safety of IGF-1 DES(1-3)?**

t are the main concerns regarding the safety of IGF-1 DES(1-3)?** A: Key safety concerns include the potential for stimulating unwanted tissue growth (including existing cancers), the risk of hypoglycemia, and local injection site reactions. The lack of extensive human clinical trial data means that the full spectrum of potential side effects and long-term risks is not well-understood. (Source: general understanding of growth factor biology and lack of human research).

peptideInjectable

IGF-1 DES(1-3)

Also known as: IGF-1 DES

Half-life

0.5 h

Typical timing

pre_workout

Food rule

either

Default unit

mcg

Studied for

Muscle & Strength Recovery & Healing

Overview

IGF-1 DES(1-3) is a modified form of Insulin-like Growth Factor 1 (IGF-1), a naturally occurring hormone. The "DES(1-3)" designation indicates that the first three amino acids (Glycine-Proline-Glutamic acid) at the N-terminus of the IGF-1 molecule have been removed. This alteration gives IGF-1 DES(1-3) a higher affinity for the IGF-1 receptor compared to native IGF-1, and also results in a reduced binding affinity to IGF-binding proteins (IGFBPs). IGFBPs typically regulate the bioavailability and activity of IGF-1 by sequestering it in the bloodstream. By having a lower binding affinity to these proteins, IGF-1 DES(1-3) is thought to have more local, unbound activity at target tissues. It is a peptide, meaning it is composed of a short chain of amino acids. As an investigational compound, its precise physiological roles and potential applications are still areas of ongoing research. It is sometimes explored for its potential in areas related to tissue growth and repair. (Source: PubChem, DrugBank)

Deep dive

Tap a section to expand.

Known interactions

Category rule: peptide × hormone
Note
Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.
Track bloodwork with a provider; don't assume combinations are neutral.

Frequently asked

Sources referenced

* DrugBank * PubChem * Scientific literature reviews (e.g., from *Growth Hormone & IGF Research*, *Journal of Applied Physiology*) * FDA (for regulatory status information, specifically lack of approval) * Academic databases (for preclinical studies)

Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.

Related compounds

Others in the peptide category or studied for the same goals.

Related benefits

Other compounds studied for the same benefits as IGF-1 DES(1-3).

Muscle & Strength

See all →

Recovery & Healing

See all →

Continue exploring

See every compound Stackwise catalogues for these goals.

Muscle & Strength →Recovery & Healing →Full compound library →

Track IGF-1 DES(1-3) in Stackwise

Add it to your stack. We'll schedule doses, check interactions against everything else you take, and remind you at the right time.

Studied for

Overview

Deep dive

How it works

Studied benefits

State of the evidence

Side effects

Warnings & who should avoid it

Contraindications

Do not mix with

Timing, food & half-life